HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

The immuno-oncological challenge of COVID-19

Abstract : Coronavirus disease 2019 (COVID-19) and its causative virus, SARS-CoV-2, pose considerable challenges for the management of oncology patients. COVID-19 presents as a particularly severe respiratory and systemic infection in aging and immunosuppressed individuals, including patients with cancer. Moreover, severe COVID-19 is linked to an inflammatory burst and lymphopenia, which may aggravate cancer prognosis. Here we discuss why those with cancer are at higher risk of severe COVID-19, describe immune responses that confer protective or adverse reactions to this disease and indicate which antineoplastic therapies may either increase COVID-19 vulnerability or have a dual therapeutic effect on cancer and COVID-19. Zitvogel and colleagues discuss the interplay between cancer and COVID-19 with respect to patient risk and prognosis, immune responses and potential therapies.
Document type :
Journal articles
Complete list of metadata

Contributor : Isabelle Combe Connect in order to contact the contributor
Submitted on : Tuesday, February 23, 2021 - 11:52:43 AM
Last modification on : Thursday, April 7, 2022 - 1:58:19 PM

Links full text



Lisa Derosa, Clea Melenotte, Franck Griscelli, Bertrand Gachot, Aurelien Marabelle, et al.. The immuno-oncological challenge of COVID-19. NATURE CANCER, 2020, 1 (10), pp.946-964. ⟨10.1038/s43018-020-00122-3⟩. ⟨hal-03149699⟩



Record views